These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6541429)

  • 41. Repetitive supraventricular tachycardia: clinical manifestations and response to therapy with amiodarone.
    Haines DE; Lerman BB; DiMarco JP
    Pacing Clin Electrophysiol; 1986 Jan; 9(1 Pt 1):130-3. PubMed ID: 2419843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Amiodarone in the nineties: to whom and what dosage?].
    Moro Serrano C; Hernández Madrid A; Lage Silveira J; Vivas Alvarez E; Kanjhi M
    Rev Esp Cardiol; 1995 Apr; 48(4):272-84. PubMed ID: 7740149
    [No Abstract]   [Full Text] [Related]  

  • 43. Amiodarone in atrial fibrillation.
    Blomström P; Edvardsson N; Olsson SB
    Acta Med Scand; 1984; 216(5):517-24. PubMed ID: 6524456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amiodarone for refractory cardiac arrhythmias: 10-year study.
    Leak D; Eydt JN
    CMAJ; 1986 Mar; 134(5):495-501. PubMed ID: 3948063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone.
    Mostow ND; Vrobel TR; Noon D; Rakita L
    Am Heart J; 1990 Dec; 120(6 Pt 1):1356-63. PubMed ID: 2248182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
    Coumel P; Leclercq JF; Assayag P
    Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.
    Gosselink AT; Crijns HJ; Van Gelder IC; Hillige H; Wiesfeld AC; Lie KI
    JAMA; 1992 Jun; 267(24):3289-93. PubMed ID: 1597910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Antiarrhythmic effect and side effects of amiodarone].
    Weber H; Weissel M; Haddad R; Scheibelhofer W; Konrad K; Mlczoch J; Probst P; Mainitz M
    Wien Klin Wochenschr; 1984 Sep; 96(18):685-96. PubMed ID: 6523885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias.
    Kato K
    Ann N Y Acad Sci; 1992 Jan; 644():235-45. PubMed ID: 1562118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arrhythmia and hypertrophic cardiomyopathy.
    Shakespeare CF; Keeling PJ; Slade AK; McKenna WJ
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():31-6. PubMed ID: 1307192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amiodarone therapy for life threatening or refractory cardiac arrhythmias.
    Johns JA; Harper RW; Currie PJ; Federman J; Anderson ST; Pitt A
    Aust N Z J Med; 1983 Jun; 13(3):248-56. PubMed ID: 6579938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term tolerance of amiodarone treatment for cardiac arrhythmias.
    Smith WM; Lubbe WF; Whitlock RM; Mercer J; Rutherford JD; Roche AH
    Am J Cardiol; 1986 Jun; 57(15):1288-93. PubMed ID: 3717027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapy of arrhythmias in hypertrophic cardiomyopathy].
    Rapezzi C; Spirito P
    G Ital Cardiol; 1995 Nov; 25(11):1443-6. PubMed ID: 8682242
    [No Abstract]   [Full Text] [Related]  

  • 54. Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient.
    Leak D
    Am Heart J; 1986 Mar; 111(3):456-62. PubMed ID: 3953353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias].
    Ricevuti A; Bianchi C; Bonifazi C; Coppetti S; Ferrari O; Rinaldo R; Rizzi M; Tavecchi L; Zampaglione G; Ziletti G; Distante S
    G Ital Cardiol; 1981; 11(6):812-9. PubMed ID: 7319187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy.
    Savage DD; Seides SF; Maron BJ; Myers DJ; Epstein SE
    Circulation; 1979 May; 59(5):866-75. PubMed ID: 154981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone.
    Marchlinski FE; Buxton AE; Flores BT; Doherty JU; Waxman HL; Josephson ME
    Am J Cardiol; 1985 Mar; 55(6):709-12. PubMed ID: 3976513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of amiodarone during long-term treatment of potentially dangerous ventricular arrhythmias in patients with chronic stable ischemic heart disease.
    Kaski JC; Girotti LA; Elizari MV; Lázzari JO; Goldbarg A; Tambussi A; Rosenbaum MB
    Am Heart J; 1984 Apr; 107(4):648-55. PubMed ID: 6702558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical efficacy of amiodarone as an antiarrhythmic agent.
    Rosenbaum MB; Chiale PA; Halpern MS; Nau GJ; Przybylski J; Levi RJ; Lázzari JO; Elizari MV
    Am J Cardiol; 1976 Dec; 38(7):934-44. PubMed ID: 793369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.